News UCB

Equities

UCB

BE0003739530

Real-time Euronext Bruxelles Other stock markets 07:27:24 2024-05-09 am EDT			5-day change	1st Jan Change
118.8 ^EUR	-2.06%		-2.54%	+50.51%

Apr. 11	Berenberg Reiterates UCB's Purchase Rating, Raises PT	MT
Apr. 11	UCB : Berenberg, Buy, raises its price target	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UCB : presents final open-label extension F®▼(fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting	May. 08	PU
UCB - Acquisition of own shares	May. 06	AQ
UCB : Acquisition of own shares	Apr. 26	PU
Pioneering innovation, fueling growth: UCB's commitment to delivering differentiated solutions	Apr. 26	PU
Ex-dividend day for final dividend	Apr. 25	FA
UCB : General Meeting of Shareholders 2024	Apr. 25	PU
UCB : receives European Commission approval for BIMZELX▼(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa	Apr. 22	PU
UCB : FINTEPLA▼ (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)	Apr. 17	PU
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology Annual Meeting	Apr. 15	AQ
UCB : Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY▼ (romosozumab) can help to close the treatment gap in osteoporosi	Apr. 12	PU
UCB : presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting	Apr. 12	PU
Berenberg Reiterates UCB's Purchase Rating, Raises PT	Apr. 11	MT
UCB : Berenberg, Buy, raises its price target	Apr. 11	CF
UCB : Acquisition of own shares - 2024	Apr. 06	PU
UCB: new indication in sight for Bimzelx in the USA	Apr. 04	CF
UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx	Apr. 04	CI
UCB : FDA Accepts Supplemental Biologics License Applications for BIMZELX (bimekizumab-bkzx) for Moderate to Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations	Apr. 04	PU
Share Repurchase Program 2024 to cover UCB's Long Term Incentive Plans for employees	Apr. 01	AQ
UCB : Share Repurchase Program 2024 to cover UCB's Long Term Incentive Plans for employees	Mar. 29	PU
UCB : receives positive CHMP opinion for BIMZELX▼(bimekizumab) for the treatment of adults with moderate to severe hidradenitis suppurativa	Mar. 22	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

UCB : UCB all set to reach new highs

March 08, 2024 at 11:10 am EST